NR3C2 and heart failure: A randomized, controlled clinical study investigated the efficacy of MR antagonists in patients with cardiac diastolic dysfunction or heart failure with preserved ejection fraction and found that MR antagonists decreased cardiac fibrosis and improved cardiac diastolic dysfunction, suggesting MR signaling as a key contributor of cardiac diastolic dysfunction and heart failure (Pandey et al. 2015).